Introduction
============

Breast cancer is the disease most extensively studied by gene expression profiling of primary tumors from patient populations \[[@B1]-[@B21]\]. Despite this effort, the research results are still fragmented. Disparate signatures have been proposed, either directly from breast cancer expression profiles \[[@B10]-[@B12],[@B18],[@B19],[@B21],[@B22]\] or translated from model systems \[[@B1],[@B23],[@B24]\], with little agreement in the constituent genes. Fan and colleagues \[[@B25]\] recently compared the prognostic ability of the intrinsic subtypes and four prognostic signatures in 295 patients. They noted concordance in the risk classification, which suggests potential equivalence between some of these signatures. However, these signatures have been examined in only one dataset and the study did not fully elucidate how the different genes were related to one another nor did it examine the contribution of well-known biological processes of breast cancer tumorigenesis to their prognostic performance.

To address these issues, we undertook the largest meta-analysis of publicly available gene expression and clinical data, which are comprised of 2,833 breast tumors \[[@B1]-[@B21]\]. We used the concept of \'coexpression\' modules (comprehensive lists of genes with highly correlated expression) associated with important biological processes in breast cancer to reveal the common thread connecting molecular subtyping and several prognostic signatures. Their prognostic values, adjusted for the conventional clinicopathological variables, were studied in a database of 2,833 patients with breast cancer in order to arrive at solid conclusions. Finally, we went a step further to characterize the constituent genes of these signatures and to study how they contribute to their prognostic power.

Materials and methods
=====================

Detailed descriptions of the methods can be found in Additional data file [1](#S1){ref-type="supplementary-material"}. A brief summary is outlined here.

Preparation of expression data
------------------------------

We collected publicly available datasets from journal articles and repositories such as Gene Expression Omnibus (GEO) and ArrayExpress, selecting those with a medium to large sample size (Table [1](#T1){ref-type="table"}). Since publications sometimes used the same patients, datasets with unique patients were introduced (identified by the \'dataset symbols\' in Table [1](#T1){ref-type="table"}) by merging some original datasets or removing redundant patients. The collection includes datasets produced on whole-genome microarrays, small diagnostic arrays, and reverse transcription-polymerase chain reaction panels, totaling 2,833 expression profiles. Hybridization probes were mapped to Entrez GeneID \[[@B26]\] through sequence alignment against RefSeq mRNA in the (NM) subset, similar to the approach of Shi and colleagues \[[@B27]\], using RefSeq version 21 (2007.01.21) and Entrez database version 2007.01.21. When multiple probes were mapped to the same GeneID, the one with the highest variance in a particular dataset was selected to represent the GeneID. The numbers of distinct GeneIDs obtained for each dataset are shown in Table [1](#T1){ref-type="table"}. The normalized, log-transformed expression measures as published by the original studies were used. Meta-analyses were performed on the union of all 17,198 genes. Summary statistics of absent genes were considered as missing values. Summaries of the availability and compositions of important clinical variables for each dataset are shown in Figure 1 of Additional data file [2](#S2){ref-type="supplementary-material"}.

![**Breast tumor characterization using module scores**. **(a)**Joint distribution between the estrogen and ERBB2 amplification scores in example datasets. Clusters are identified by Gaussian mixture models with three components. The ellipses correspond to the 95% cumulative probability around the cluster centers. The clusters are designated as tumor types ER^-^/ERBB2^-^, HER2^+^, and ER^+^/HER2^-^. HER2^+^tumors show intermediate estrogen scores. **(b)**Dot histograms showing dependence of proliferation score on the subtypes. The median and quartiles for each group are shown by the box plot. ER^-^/ERBB2^-^and HER2^+^tumors show high proliferation scores, whereas ER^+^/HER2^-^tumors show a wide range of proliferation scores. The distributions of the intrinsic subtypes (colored dots), BRCA1 mutations, and p53 mutations are shown in datasets where they are available. ER, estrogen receptor.](bcr2124-1){#F1}

###### 

Publicly available gene expression data from breast cancer studies

  Dataset symbol               Number of arrays                                            Institution                                                                         Reference(s)                                     Platform              Data source             Number of GeneIDs
  ---------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------------- ------------------------------------------------ --------------------- ----------------------- -------------------
  Genomic platforms                                                                                                                                                                                                                                                           
  NKI                          337                                                         Nederlands Kanker Instituut (Amsterdam, The Netherlands)                            \[[@B19],[@B20]\]                                Agilent               Author\'s website       13,120
  EMC                          286                                                         Erasmus Medical Center (Rotterdam, The Netherlands)                                 \[[@B21]\]                                       Affymetrix U133A      GEO: GSE2034            11,837
  UPP                          249                                                         Karolinksa Institute (Uppsala, Sweden)                                              \[[@B3],[@B11]\]                                 Affymetrix U133A,B    GEO: GSE4922            15,684
  STOCK                        159                                                         Karolinska Institute (Stockholm, Sweden)                                            \[[@B3],[@B13]\]                                 Affymetrix U133A,B    GEO: GSE1456            15,684
  DUKE                         171                                                         Duke University (Durham, NC, USA)                                                   \[[@B8]\]                                        Affymetrix U95Av2     Author\'s website       8,149
  UCSF                         161 + 8                                                     University of California at San Francisco (USA)                                     \[[@B9]\]                                        cDNA                  Author\'s website       6,178
  UNC                          143 + 10                                                    University of North Carolina (Chapel Hill, NC, USA)                                 \[[@B7]\]                                        Agilent HuA1          Author\'s website       13,784
  NCH                          135                                                         Nottingham City Hospital (Nottingham, UK)                                           \[[@B12]\]                                       Agilent HuA1          AE: E-UCON-1            13,784
  STNO                         115 + 7                                                     Stanford University (Palo Alto, CA, USA)/Norwegian Radium Hospital (Oslo, Norway)   \[[@B16]\]                                       cDNA                  Author\'s website       5,614
  JRH1                         99                                                          John Radcliffe Hospital (Oxford, UK)                                                \[[@B17]\]                                       cDNA                  Journal\'s website      4,112
  JRH2                         61                                                          John Radcliffe Hospital                                                             \[[@B18]\]                                       Affymetrix U133A      GEO: GSE2990            11,837
  MGH                          60                                                          Massachusetts General Hospital (Boston, MA, USA)                                    \[[@B10]\]                                       Agilent               GEO: GSE1379            11,421
  expO                         239                                                         International Genomic Consortium                                                    \[[@B41]\]                                       Affymetrix U133v2     GEO: GSE2109            16,634
  TGIF1                        49                                                          EORTC trial 10994                                                                   \[[@B5]\]                                        Affymetrix U133A      GEO: GSE1561            11,837
  BWH                          40 + 7                                                      Brigham and Women\'s Hospital (Boston, MA, USA)                                     \[[@B14]\]                                       Affymetrix U133v2     GEO: GSE3744            16,634
  Small diagnostic platforms                                                                                                                                                                                                                                                  
  TRANSBIG                     253                                                         TRANSBIG Consortium                                                                 \[[@B2]\]                                        Agilent               AE: E-TABM-77           1,052
  EMC2                         180                                                         Erasmus Medical Center                                                              \[[@B6]\]                                        Affymetrix (custom)   GSE3453                 86
  HPAZ                         96                                                          Hospital La Paz (Madrid, Spain)                                                     \[[@B4]\]                                        RT-PCR                Appendix of \[[@B4]\]   61
  Total                        2,865 = 2,833 carcinomas + 32 nonmalignant breast tissues   Number of the union of all GeneIDs:                                                 17,198                                                                                         
                                                                                                                                                                               Number of GeneIDs common to genomic platforms:   1,963                                         

Datasets UNC, STNO, UCSF, and BWH include a small number of normal breast or fibroadenoma tissue samples. AE, ArrayExpress (accession); Affymetrix, Affymetrix, Inc., Santa Clara, CA, USA; Agilent, Agilent Technologies, Inc., Santa Clara, CA, USA; EORTC, European Organization for Research and Treatment of Cancer; GEO, Gene Expression Omnibus (accession); RT-PCR, reverse transcription-polymerase chain reaction.

Identifying coexpression modules
--------------------------------

The expression levels of the prototype genes on the log~2~scale were used as explanatory variables in multiple regression with the Gaussian error model, using the following equation (gene symbols stand for their log expression, and coefficients are omitted for clarity):

where the response variable *Y*~*i*~is the expression of gene *i*. This model is fitted separately for each gene *i*in the array. The association between gene *i*and prototype *j*(in the presence of or conditional on all other prototypes) is tested using the *t*statistic for each coefficient. Because the *t*statistics for different datasets have different degrees of freedom, we put them all on the same scale by transforming them to the corresponding cumulative probabilities and then to *z*scores using the inverse standard normal cumulative distribution function. The *z*scores were combined meta-analytically across datasets using the \'inverse normal method\'. The linear model above was fitted separately to each gene in each dataset, and the *z*scores were combined meta-analytically over multiple studies using the inverse normal method \[[@B28]\]. To select genes that are most strongly associated with the prototypes, we use a stringent criterion of \|*z*\| ≥ 16, which is well above \|*z*\| ≈ 5 that corresponds to a Bonferroni-corrected *P*value of 0.05.

Module scores
-------------

For a specific dataset, the module score is computed for each sample as

$$module\quad score = {\sum\limits_{i}{w_{i}x_{i}}}/{\sum\limits_{i}\left| w_{i} \right|},$$

where *x*~*i*~is the expression of a gene in the module that is present in the dataset\'s platform. *w*~*i*~is either +1 or -1, depending on the sign of the *z*score of the association with the prototypes.

Clustering and multimodality tests
----------------------------------

To cluster the tumors based on the ESR1 and ERBB2 module scores, Gaussian mixture models \[[@B29]\] with equal and diagonal variance for all clusters were fitted. For testing multimodality, we used the likelihood ratio test statistics between the fitted model for the tested number of components, *k*, versus the alternative model with *k*- 1 components. The statistical significance of the number of components was assessed by parametric bootstrapping. Each tumor was automatically classified as estrogen receptor-negative (ER^-^)/HER2^+^, HER2^+^, or ER^+^using the maximum posterior probability of membership in the clusters.

Survival analysis
-----------------

Survival curves and 5-year survival rates in forest plots were based on Kaplan-Meier estimates, with the Greenwood method used for computing the 95% confidence intervals \[[@B30]\]. Hazard ratios between two groups were calculated using Cox regression. Stratified Cox regression was used to compute total hazard ratios in forest plots and multivariate analysis, using the dataset as the stratum indicator, thus allowing for different baseline hazard functions between cohorts. Cox regression was also used to compute gene-by-gene associations with survival, treating the log expression measures as continuous explanatory variables. The gene-wise *z*scores were combined across datasets using the inverse normal meta-analytical methods. Distant relapse-free survival (DRFS) was considered as an event for our survival analysis, which includes distant recurrence, death from breast cancer, death from a cause other than breast cancer, and death from an unknown cause.

Results
=======

Prototype-based coexpression module analysis
--------------------------------------------

To perform this meta-analysis including several heterogeneous datasets and different microarray platforms, we used the concept of coexpression modules. To identify these modules, we applied a supervised approach whereby three \'prototype\' genes representing three key biological processes in breast cancer (namely, proliferation, ER, and HER2 amplification signaling) were selected. The genes chosen as their prototypes were, respectively, *ESR1*, *ERBB2*, and *AURKA*(aurora-related kinase 1, also known as *STK6*or *STK15*).

Using the meta-analysis scheme described above, we were able to identify genes whose expression was significantly associated with each chosen prototype (Additional data file [3](#S3){ref-type="supplementary-material"}). The coexpression patterns of the genes are shown by heatmaps in Figure 2 of Additional data file [2](#S2){ref-type="supplementary-material"}. Each module contains highly correlated or anticorrelated genes, as shown by the vertical color patterns. The annotation of the modules shows that they correspond well to the expected biological processes, as many ER-related, HER2-related, and proliferation genes were included in the ER and HER2 signaling and proliferation modules, respectively. For our further analysis, the correlated gene expression measures in a module (which provide redundant information) are averaged into a single number called a \'module score\'.

![Survival analysis of groups based on module scores. Kaplan-Meier analysis for distant relapse-free survival (DRFS) of systemically untreated **(a)**and treated **(b)**patient groups. The ER^+^subgroup is split into ER^+^/HER2^-^/L and ER^+^/HER2^-^/H (low and high proliferation, respectively). Vertical bars on the curves are 95% confidence intervals for the Kaplan-Meier survival estimates. Forest plot representation of the 5-year survival estimates and hazard ratios for DRFS of individual datasets in the systemically untreated **(c)**and treated **(d)**populations. The length of horizontal bars and the width of the diamonds of the \'Total\' correspond to 95% confidence intervals. Missing bars are unavailable data. Multivariate analysis representation in which all the variables are available in systemically untreated **(e)**and treated **(f)**patients. ER, estrogen receptor; HR, hazard ratio.](bcr2124-2){#F2}

Module scores for tumor subtyping
---------------------------------

To automatically assign these large numbers of tumors into the subtypes according to the given module, we applied the Gaussian mixture models \[[@B29]\] to the module scores of the three processes. Only three natural clusters, based on multimodality tests, can be identified. The ER and HER2 module scores were bimodally distributed, but the proliferation module was not. Furthermore, the combination of the ER and HER2 module scores does not produce four clusters that would have been observed if the scores were independent (Figure [1a](#F1){ref-type="fig"}). Instead, ERBB2^+^tumors showed an intermediate level of ER module values, and we therefore did not consider the distinction of ERBB2^+^into ER^+^or ER^-^to be supported by continuous value gene expression levels. We will refer to three groups as ER^-^/HER2^-^, HER2^+^, and ER^+^/HER2^-^tumors, which correspond roughly to the intrinsic subtypes of basal-like, *her2*, and combined luminal A/B subtypes, respectively, as defined by the Stanford group \[[@B15]\].

Concerning proliferation, Figure [1b](#F1){ref-type="fig"} shows that, while ER^-^/HER2^-^and HER2^+^tumors have mostly high proliferation scores, ER^+^/HER2^-^tumors display a wide range of values, encompassing the low values of normal breast tissue (see dataset UNC) and the high values typical for ER^-^/HER2^-^and HER2^+^tumors. For our further analysis, we denote the ER^+^/HER2^-^low- and high-proliferation tumors as ER^+^/HER2^-^/L and ER^+^/HER2^-^/H, corresponding to the luminal A and B subdivisions of the intrinsic subtypes, respectively. Interestingly, we did not see natural clustering (bimodality) in the distribution of proliferation scores as was the case with the ER and ERBB2 modules.

The relationship between module scores and some gene mutations could also be examined. Almost all BRCA1-mutated tumors are confined to ER^-^tumors (Figure [1b](#F1){ref-type="fig"}), confirming the hypothesis that ER^-^(\'basal-like\') tumors are phenocopies of BRCA1-mutated tumors \[[@B14]\]. This is also supported by the strong overexpression of LMO4, a suppressor of BRCA1 function \[[@B31]\], in ER^-^tumors. p53 mutations may appear in the three subtypes, but mostly confined to the highly proliferative tumors. It is not clear whether their association with ER^-^/HER2^-^and HER2^+^tumors is related to the pathways of these receptors or is merely an indirect effect of the mutations\' association with proliferation.

Prognostic value of the molecular subtypes according to the module scores
-------------------------------------------------------------------------

The attractiveness of gene expression prognostic signatures for clinical applications comes from their ability to identify a group of patients with a good survival rate that is acceptable to spare patients from aggressive chemotherapy. Here, we investigated whether classifications based on the easily interpretable module scores could achieve such clinical relevance.

Figure [2](#F2){ref-type="fig"} shows a Kaplan-Meier analysis for the DRFS of systemically untreated (Figure [2a](#F2){ref-type="fig"}) patients and those treated (Figure [2b](#F2){ref-type="fig"}) with adjuvant chemotherapy and/or endocrine therapy with available clinical information, according to four main subtypes based on the module scores. The ER^+^/HER2^-^/L subtype showed a much better DRFS than the three others in both untreated and treated populations, with 90% of patients alive at 5 years of follow-up. Because there is no statistical difference in survival between the ER^-^, HER2^+^, and ER^+^/HER2^-^/H subtypes and because the risk of recurrence for patients in these groups is clinically still too high, we pooled them into the \'poor\' prognosis group, in contrast to the \'good\' ER^+^/HER2^-^/L subtype, for further survival analysis. The consistency of the prognostic value across datasets is demonstrated by the forest plots in Figures [2c](#F2){ref-type="fig"} and [2d](#F2){ref-type="fig"}, where the results of the analysis of individual datasets are concisely summarized by the 5-year survival estimates and hazard ratios between the \'good\' and \'poor\' groups. Interestingly, the \'good\' prognosis group showed a better DRFS than the \'poor\' prognosis group in both untreated and systemically treated populations.

The interactions between the module-based risk groups and conventional clinicopathological prognostic variables are tested in multivariable Cox regression analysis for DRFS in both untreated (Figure [2e](#F2){ref-type="fig"}) and treated (Figure [2f](#F2){ref-type="fig"}) populations. The module-based classification added a strong prognostic effect over all other clinical factors. Confirming previous studies \[[@B18],[@B32]\], the effect of histological grade is much reduced and can be explained by the refinement of intermediate grade into two groups with very different survival rates. Interestingly, lymph node status and tumor size remain as independent prognostic factors.

Dissecting gene expression prognostic signatures according to the module scores
-------------------------------------------------------------------------------

Although Fan and colleagues \[[@B25]\] noted the similarity of the performance and patient classifications of the intrinsic subtypes and four prognostic signatures on the same dataset, they did not provide a biological rationale for this finding. In our study, we performed more detailed and extensive analysis to better understand how disparate gene lists may give rise to potentially equivalent prognostic signatures.

Using our meta-analytical approach, we first sought to identify individual genes that were associated with survival by calculating the meta-analytical *z*scores of gene-by-gene Cox regression. To gain further insight into the biological significance of these prognostic genes, we investigated their correlation with the coexpression module prototypes. We were able to identify 524 genes that were significantly associated with survival, even under a stringent Bonferroni multiple testing correction (data not shown). Of the 524 genes, 71% were strongly coexpressed with proliferation, 26% with ER, and 2.2% with ERBB2 prototypes, highlighting the importance of proliferation-related genes for prognostication in breast cancer.

A similar analysis was performed with respect to several published prognostic signatures (Table [2](#T2){ref-type="table"}). Indeed, many of the genes included in these signatures were confirmed to be individually prognostic in the whole dataset collection (Figure 3 of Additional data file [2](#S2){ref-type="supplementary-material"}). Interestingly, many of these individually prognostic genes were also highly correlated with the proliferation module prototype and not with the other two modules, suggesting that proliferation may be the common driving force of several prognostic signatures.

![Signature comparison. The prognostic performance of the signatures is compared by the forest plots of hazard ratio and plotted as vertical color bars for comparison. Most signatures show similar performance. Prognostic performance for distant relapse-free survival (DRFS) of the signatures using partial signatures containing only proliferation genes in the untreated **(a)**and treated **(c)**populations. The performance of most signatures is not degraded; in fact, it is improved for p53-32. Prognostic performance for DRFS of the signatures using partial signatures containing nonproliferation genes in the untreated **(b)**and treated **(d)**populations.](bcr2124-3){#F3}

###### 

Prognostic signatures

  Signature symbol   Reference    Associated variables in gene selection procedure          Number of genes   
  ------------------ ------------ --------------------------------------------------------- ----------------- ------------------
                                                                                            Original probes   Mapped to geneID
                                                                                                              
  ONC-16             \[[@B42]\]   Biological knowledge; refined by patient outcome          16                16
  NKI-70             \[[@B19]\]   Patient outcome                                           70                52
  EMC-76             \[[@B21]\]   Patient outcome, stratified by estrogen receptor status   60 + 16           48 + 12
  NCH-70             \[[@B12]\]   Patient outcome                                           70                69
  CON-52             \[[@B43]\]   Patient outcome, consensus                                52                50
  p53-32             \[[@B11]\]   p53 mutation                                              32                19
  CSR                \[[@B24]\]   Fibroblast core serum response                            512               457
  GGI-128            \[[@B18]\]   Histological grade                                        128               98
  CCYC               \[[@B44]\]   Periodic expression in cell cycle progression             NA                126

NA, not applicable.

To further demonstrate our hypothesis, we divided each signature into two \'partial signatures\': one with only proliferation genes and the other with the complementary nonproliferation genes (Figure [3](#F3){ref-type="fig"}; see Figure 4 of Additional data file [2](#S2){ref-type="supplementary-material"} for detailed analysis). Interestingly, when only proliferation genes were used, the overall performance was not degraded; in fact, it even improved for some signatures (p53-32) in both untreated (Figure [3a](#F3){ref-type="fig"}) and treated (Figure [3c](#F3){ref-type="fig"}) populations. In contrast, the nonproliferation partial signatures typically showed degraded performance (Figures [3b](#F3){ref-type="fig"} and [3d](#F3){ref-type="fig"}). These results show that proposed signatures may contain genes that are unnecessary or even detrimental to their performance. These results thus extend the findings of Fan and colleagues \[[@B25]\] to a much larger sample size and for several additional signatures, revealing for the first time the importance of proliferation genes as a common driving force behind the performance of all of the prognostic signatures studied in this investigation.

![Patient classifications made by example signatures applied to representative datasets, showing that the different signatures are essentially detecting as low-risk the low-proliferation subset of ER^+^/ERBB2^-^tumors. ER, estrogen receptor.](bcr2124-4){#F4}

Finally, the relationship between prognostic signatures and the molecular classification based on the coexpression modules was investigated by looking at the risk classifications on the plots of proliferation scores versus the molecular subtypes shown in Figure [4](#F4){ref-type="fig"} (see Figure 4 of Additional data file [2](#S2){ref-type="supplementary-material"} for analysis on all datasets). Most signatures identified the low-proliferation subset of ER^+^/HER2^-^tumors as low-risk, whereas almost all high-proliferation ER^+^, ER^-^/HER2^-^, and HER2^+^tumors were classified as high-risk. These results suggest that these prognostic signatures function mostly by identifying tumors that have high expression of proliferation genes, regardless of the subtyping based on ER or HER2. They still correctly classify ER^-^/HER2 and HER2^+^as high-risk by virtue of elevated expression of proliferation genes.

Discussion
==========

Several breast cancer studies have generated a large number of arrays with complex genomic data, and an initial effort was made to compare the prognostic performance of the intrinsic subtypes and four signatures in one dataset \[[@B25]\]. In the present meta-analysis, we analyzed data from 2,833 patients to have the power to address the following questions: How are different signatures related with respect to prognostication? Should clinical, pathological, and currently used biomarkers be integrated into this process? What is the role of individual genes in a signature, and what is their biological meaning?

Using our meta-analytical approach, we confirmed the presence of four stable breast cancer molecular subtypes as originally reported by Perou and colleagues \[[@B33]\], whereas the normal-like subtype was not verified. Both ER^-^/HER2^-^and HER2^+^subtypes were characterized by high proliferation, whereas the ER^+^/HER2^-^subtype was divided into low- and high-proliferation tumors with different clinical outcomes. The widely observed prognostic powers of ER and HER2 are therefore only indirect effects.

Furthermore, the above results have important clinical implications since they suggest that all investigated prognostic signatures are equivalent. This will be further validated when the results from the currently accruing MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) \[[@B34]\] and TAILORX (Trial Assigning IndividuaLized Options for Treatment \[Rx\]) \[[@B35]\] trials are reported. For the ER^-^/HER2^-^and HER2^+^patients, new prognostic signatures, which do not rely on proliferation genes, are urgently needed. Initial efforts to improve prognosis in the above high-risk subgroups were recently reported \[[@B36],[@B37]\].

Moreover, rather than treating the signatures as black boxes, the connection to the breast cancer biology has been elucidated. Using this approach, we demonstrated that several previously reported prognostic signatures, despite the disparity in their gene lists, carry similar information with regard to prognostication. Although it may be argued that microarray measurements are merely alternative ways to monitor well-known processes such as proliferation, ER, or HER2 signaling, their results are not perfectly concordant with conventional variables. For example, although the proliferation module score and histological grade both aim to measure cell proliferation, the former is more informative \[[@B18]\]. We observed that HER2^+^tumors showed intermediate ER module activity, which is not obvious from the traditional ER and HER2 status using conventional assays. These examples suggest that the assessment of several genes from a coexpression module may provide a more accurate quantification of a whole transcriptional process than using single-gene markers or histopathological variables.

Blamey \[[@B38]\] distinguished independent prognostic factors into those related to the extent of tumor progression (such as lymph node status and tumor size) and those related to a tumor\'s intrinsic aggressiveness (such as histological grade and mitotic rate) and found only that the prognostic roles of many markers, such as ER, progesterone receptor, and p53, were overshadowed by histological grade. Our results confirmed these observations, as proliferation genes are even better indicators of tumor grade \[[@B18]\]. The proliferation score already contains the poor prognosis information attributable to various sources: for example, ERBB2 amplification (with or without BRCA1 mutation), p53 mutation, or yet unknown factors specifically affecting half of ER^+^(luminal) tumors. We still see the prognostic effect of lymph node status and tumor size, suggesting that they influence outcome through their own independent paths.

Despite the lack of direct prognostic impact of ER and ERBB2 genes, the coexpression modules for these processes that we identified are still useful. Genes in the proliferation module are already targeted by several chemotherapeutic agents, but less harmful drugs are more desirable. ER^+^/HER2^-^tumors are treatable to some extent by hormone therapy \[[@B39]\] (targeting ESR1 signaling), and HER2^+^tumors by trastuzumab \[[@B40]\] (targeting ERBB2). However, drugs specifically targeting ER^-^/HER2^-^tumors have not yet been established. Furthermore, the fact that many breast tumors remain unresponsive to existing drugs warrants further searches for alternative targets, possibly compensatory genes in the same pathway. Our analysis provides lists of genes coexpressed with these two processes, and these lists should be more stable than previously published ones because they are identified from a large data collection from multiple platforms.

Finally, we have also shown that using coexpression modules is a versatile tool for unifying apparently disparate results. Although coexpression does not imply direct physical interaction, the highly correlated genes in a module can be considered surrogate markers of one another and of the same underlying transcriptional process. Consequently, newly published signatures in the future can be perceived in the light of well-known modules, and a new, equivalently prognostic set of markers can be devised based on subsets of these lists.

Conclusion
==========

In summary, this study objectively evaluates several published signatures in independent cohorts from diverse microarray platforms and unifies results of previous gene expression studies in breast cancer. With respect to clinical application, we revealed connections and equivalence between traditional prognostic factors, expression-based subtyping, and prognostic signatures and provided evidence that these signatures should be tested for their ability to spare adjuvant chemotherapy mainly in the low-proliferation subgroup of patients with ER^+^tumors. With respect to disease biology, we consolidated the gene lists of the major processes, providing more reliable candidates for biomarkers and therapeutic targets than those produced by single-dataset studies. Finally, we provided a new methodological framework, also applicable to other diseases, for using heterogeneous microarray datasets to uncover consistent biological relationships and to consolidate proposed signatures.
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